Beijing Shuyi Hospital
11
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)
Role: collaborator
China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）
Role: collaborator
Changes of Cognitive Function and Brain Magnetic Resonance in Maintenance Hemodialysis Patients With Diabetes Mellitus
Role: collaborator
Effect and Safety of Surgical Intervention for Severe Spontaneous Intracerebral Hemorrhage Patients on Long-term Oral Antiplatelet Treatment
Role: collaborator
Xingnaojing for Mild-to-severe Acute Ischemic Stroke
Role: collaborator
LIFT-plug vs LIFT, a RCT Trial
Role: collaborator
Services Mapping Among Older Adults With Hip Fracture
Role: collaborator
Intracranial Artery Stenosis Magnetic Resonance Imaging: Aetiology and Progression
Role: collaborator
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage
Role: collaborator
Etiology and Prognostic Risk Factors of Intracerebral Hemorrhage in Beijing
Role: collaborator
A Multi-Center Study of Rehabilitation to Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
Role: collaborator
All 11 trials loaded